CD274 and ovarian cancer: Responses occurred in patients with NSCLC who had received prior PD-(L)1 therapy, as well as in a patient with triple-negative breast cancer and a patient with ovarian cancer, neither of whom had received prior anti−PD-(L)1 treatment.